Ann: RHS Investor Presentation May 2017, page-10

It was a smart play by the company to word document as such but the product has been available for some time and until it translates to positive revenues this is following a similar trend to many Bio-Pharma companies in which they pump stock up to hold a 7-10 day average well above the low, followed by a heavily reduced CR @ 20% below the moving average, to further continue research.

Until I hear revenue based announcements or see the SP slide back below 10c this is a sit on the sidelines play for me. Look at the 2014 pattern, this to me is going to follow a similar trend unless they can indicate some major deals, that is why Pharma is such a good industry to short (Valeant being a prime example).

GLTH though as I could be wrong and it is only my opinion.